Berberine,Nonalcoholic fatty liver disease,Lipid metabolism,SIRT1-FoxO1-SREBP2 ," /> Berberine,Nonalcoholic fatty liver disease,Lipid metabolism,SIRT1-FoxO1-SREBP2 ,"/> Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis
Search JIM Advanced Search

Journal of Integrative Medicine ›› 2021, Vol. 19 ›› Issue (6): 545-554.doi: 10.1016/j.joim.2021.09.003

• Original Experimental Research • Previous Articles     Next Articles

Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis

Meng-ya Shana, Ying Daia, Xiao-dan Rena, Jing Zhenga, Ke-bin Zhangb, Bin Chenc, Jun Yand, Zi-hui Xua   

  1. a. Department of Integrative Medicine, Xinqiao Hospital, Army Medical University, Chongqing 400037, China
    b. National Drug Clinical Trail Institution, Xinqiao Hospital, Army Medical University, Chongqing 400037, China
    c. Department of Biochemistry and Molecular Biology, Army Medical University, Chongqing 400038, China
    d. Department 1, Research Institute of Surgery & Daping Hospital, Army Medical Center of Chinese People’s Liberation Army, Army Medical University, Chongqing 400042, China
  • Received:2021-01-26 Accepted:2021-05-31 Online:2021-11-12 Published:2021-12-16
  • Contact: Zi-hui Xu


To investigate effects of berberine (BBR) on cholesterol synthesis in HepG2 cells with free fatty acid (FFA)-induced steatosis and to explore the underlying mechanisms.


A steatosis cell model was induced in HepG2 cell line fed with FFA (0.5 mmol/L, oleic acid:palmitic acid = 2:1), and then treated with three concentrations of BBR; cell viability was assessed with cell counting kit-8 assays. Lipid accumulation in cells was observed through oil red O staining and total cholesterol (TC) content was detected by TC assay. The effects of BBR on cholesterol synthesis mediators were assessed by Western blotting and quantitative polymerase chain reaction. In addition, both silent information regulator 1 (SIRT1) and forkhead box transcription factor O1 (FoxO1) inhibitors were employed for validation. 


FFA-induced steatosis was successfully established in HepG2 cells. Lipid accumulation and TC content in BBR groups were significantly lower (P < 0.05, P < 0.01), associated with significantly higher mRNA and protein levels of SIRT1(P < 0.05, P < 0.01), significantly lower sterol regulatory element-binding protein 2 (SREBP2) and 3-hydroxy 3-methylglutaryl-CoA reductase levels (P < 0.05, P < 0.01), as well as higher Acetyl-FoxO1 protein level (P < 0.05, P < 0.01) compared to the FFA only group. Both SIRT1 inhibitor SIRT1-IN-1 and FoxO1 inhibitor AS1842856 blocked the BBR-mediated therapeutic effects. Immunofluorescence showed that the increased SIRT1 expression increased FoxO1 deacetylation, and promoted its nuclear translocation.


BBR can mitigate FFA-induced steatosis in HepG2 cells by activating SIRT1-FoxO1-SREBP2 signal pathway. BBR may emerge as a potential drug candidate for treating nonalcoholic hepatic steatosis. 

Key words: Berberine, Nonalcoholic fatty liver disease, Lipid metabolism, SIRT1-FoxO1-SREBP2

No related articles found!
Full text



[1] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[2] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[3] Zhao-guo Li . A discussion of English translation of 1995 and 1997 Chinese National Standards of Traditional Chinese Medical Terminologies for Clinical Diagnosis and Treatment. Journal of Chinese Integrative Medicine, 2010, 8(11): 1090-1096
[4] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205
[5] Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228
[6] Liang-ping Hu, Xiao-lei Bao. Three-factor designs unable to examine the interactions (Part 2). Journal of Chinese Integrative Medicine, 2012, 10(11): 1229-1232
[7] Ming-qing Wei , Jin-zhou Tian , Jing Shi , Fu-yun Ma , Ying-chun Miao , Yong-yan Wang. Effects of Chinese medicine for promoting blood circulation and removing blood stasis in treating patients with mild to moderate vascular dementia: a randomized, double-blind and parallel-controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(11): 1240-1246
[8] Xiao Zhang , Bing-bing Ning , Shuang Ren , Li-jun Zhang , Wen-meng Zhang , Jia-mei Chen , Gao-feng Chen , Hua Zhang , Yong-ping Mu , Ping Liu. Effects of Chinese herbal medicine Xiaopi Pill in preventing rats from dimethylnitrosamine-induced liver fibrosis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1286-1292
[9] Ji Chen, Qin Pan, Li-shuang Ye, Jia-ling Huang. English translation of cultural aspects of the titles of traditional Chinese medicine classics based on the skopos theory. Journal of Chinese Integrative Medicine, 2012, 10(11): 1316-1320
[10] Kai Qu, Tian-fang Wang, Yan Zhao, Xiao-lin Xue, Xiu-yan Wu, Hua-liang Deng, Lu Yang, Li-liYu , Hong Yue, Qing-guo Wang. Common syndrome factors of traditional Chinese medicine in chronic renal failure based on the questionnaire investigation among experts. Journal of Chinese Integrative Medicine, 2010, 8(12): 1147-1152